Research reported on in this publication was supported by the following grants from the National Institutes of Health (NIH):
Bioengineered BioMask Offers Hope for Healing Facial Skin Injuries: NIH grant 1P41EB023833-01.
NIH Grant to Fund Study of Deep Brain Stimulation for Alzheimer’s: National Institute of Aging grant 1R01AG060754-01A1.
Researchers Identify Novel Molecular Mechanism Involved in Alzheimer’s: NIH grants K99/R00 AG044469, R01 AG055581, R01 AG056622, F31AG055264, F31AG054113, P50AG005136, U01AG006781; also Alzheimer’s Association grant NIRG-15-362799, BrightFocus Foundation grant A2017457S, Wake Forest Alzheimer’s Disease Core Center pilot grant P30AG049638, Wake Forest Clinical and Translational Science Institute pilot grant, and the Nancy and Buster Alvord Endowment.
Lowering Blood Pressure Reduces Risk of Cognitive Impairment: NIH contract numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C, and interagency agreement A-HL-13-002-001; clinical trial number: NCT01206062.
First-ever Model Developed for Patient-specific Treatment of Appendix Cancer: A Wake Forest Clinical and Translational Science Institute Pilot Award (NIH UL1 TR001420); also internal funding from the Comprehensive Cancer Center at Wake Forest Baptist Health.
Anti-leprosy Drug Shows Promise as Multiple Myeloma Treatment: NIH grants CA220096, CA224434, CA193981 and CA190533; a Ruth L. Kirschstein National Research Service Award F32CA189622; NIH grants CA197996, 1F99CA21245501, R01AI100157 and R01CA121044; the Jennifer Linscott Tietgen Foundation; and in part by a National Cancer Institute Cancer Center Support Grant P30CA16056 to the Roswell Park Comprehensive Cancer Center, for the Clinical Data Network and the Animal Facility.